Roche and reMYND will make Parkinson's and Alzheimer's drugs

09/7/2010 | Reuters

Roche Holding is collaborating with Belgium's reMYND to develop two of the latter's preclinical compounds, which suppress tau neurotoxicity in Alzheimer's disease and alpha-synuclein neurotoxicity in Parkinson's disease. ReMYND might receive from Roche more than $637 million in milestone fees, plus royalties.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA